キメラ抗原受容体T細胞製造プロセスのカーボンフットプリント
The carbon footprint of Chimeric Antigen Receptor-T cell manufacturing processes (原題)
Wietske van der Bijl, Bahez Gareb, Koen Klomberg, Edwin Bremer, Tom van Meerten, Thijs H. Oude Munnink, Bart G. J. Dekkers
🤖 gxceed AI 要約
日本語
CAR-T細胞療法の製造プロセスをライフサイクルアセスメントで評価し、二酸化炭素排出量を定量化した。輸送が最大の排出源であり、集中型（355.75 kg CO2e）とポイントオブケア型（72.85 kg CO2e）で大きな差があった。閉鎖系施設は開放系より排出が少なく、輸送距離の短縮とクリーンルームの最適化が削減に有効。医療分野でのカーボンフットプリント評価の枠組みを提供。
English
This study conducts a life cycle assessment of CAR-T cell manufacturing, quantifying carbon emissions. Transport is the dominant contributor, with centralized manufacturing emitting 355.75 kg CO2e versus 72.85 kg CO2e for point-of-care. Closed-system facilities emit less than open systems. Reducing transport distance and optimizing cleanroom use are key reduction strategies. Provides a framework for carbon footprint assessment in healthcare.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本の医療機関や製薬企業にとって、CAR-T製造の環境負荷を可視化する初の試みであり、医療分野の脱炭素化に向けた具体的な指標を提供する。今後、日本でも医療提供体制のカーボンフットプリント削減が求められる中で、輸送と施設運用の改善に示唆を与える。
In the global GX context
This is the first carbon footprint assessment of CAR-T manufacturing, offering a framework applicable to healthcare decarbonization globally. It highlights transport and cleanroom energy as key drivers, supporting the shift towards point-of-care manufacturing. Relevant for healthcare systems aiming to meet net-zero targets and for pharmaceutical companies addressing Scope 3 emissions.
👥 読者別の含意
🔬研究者:Provides a methodological framework for LCA in healthcare and identifies key emission hotspots in cell therapy manufacturing.
🏢実務担当者:Offers actionable insights for reducing carbon footprint in biopharmaceutical manufacturing, particularly through transport optimization and facility design.
🏛政策担当者:Highlights the environmental impact of advanced therapies, informing policies for sustainable healthcare and supply chain decarbonization.
📄 Abstract（原文）
Chimeric Antigen Receptor T (CAR-T) cell therapy is an established treatment for haematological malignancies, yet the environmental impact of its manufacturing and administration remains unexplored. As healthcare systems aim to reduce their carbon footprint, understanding the climate impact of CAR-T cell manufacturing is essential. The objective of this study was to quantify the carbon footprint, expressed in CO2-equivalents (CO2e), of CAR-T cell manufacturing and identify process steps that contribute most to CO2-emissions. A systematic life cycle assessment (LCA) of both centralized and point-of-care (PoC) CAR-T cell manufacturing processes was conducted, according to ISO14044:2006 standards. All major processes were assessed, including leukapheresis, cryopreservation, transport, manufacturing, background facilities, quality controls, and infusion. Emissions were calculated using openLCA and open-access databases. Transport was the dominant contributor to total emissions, accounting for the higher footprint of commercial CAR-T cells (355.75 kg CO2e) compared to PoC CAR-T cells (72.85 kg CO2e). In addition, open system background facilities emitted substantially more CO2 compared to closed system background facilities (85.16 vs. 25.00 kg CO2e). Reducing travel distance and optimizing cleanroom use offer the greatest potential for emission reduction. This study provides the first assessment of the carbon footprint of two established CAR-T cell manufacturing platforms and offers a framework that can be applied across a broad range of CAR-T products. It highlights transport and cleanroom energy use as key drivers of emissions, causing PoC manufacturing to substantially reduce the environmental impact by limiting long-distance transport.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1016/j.ijpx.2026.100654first seen 2026-08-30 04:44:46
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。